IRIS
CALZETTA, LUIGINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.487
AS - Asia 7.993
EU - Europa 5.203
SA - Sud America 1.122
Continente sconosciuto - Info sul continente non disponibili 841
AF - Africa 86
OC - Oceania 24
Totale 63.756
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.240
SG - Singapore 3.808
CN - Cina 1.343
IT - Italia 1.082
BR - Brasile 910
RU - Federazione Russa 835
HK - Hong Kong 814
IE - Irlanda 655
VN - Vietnam 611
KR - Corea 539
UA - Ucraina 513
FR - Francia 464
DE - Germania 441
PL - Polonia 319
GB - Regno Unito 264
FI - Finlandia 231
BD - Bangladesh 217
JP - Giappone 192
CA - Canada 138
SE - Svezia 127
IN - India 113
NL - Olanda 88
ID - Indonesia 74
AR - Argentina 67
ES - Italia 47
MX - Messico 41
IQ - Iraq 34
EC - Ecuador 33
ZA - Sudafrica 30
PK - Pakistan 29
TR - Turchia 28
VE - Venezuela 27
AT - Austria 26
CO - Colombia 26
UZ - Uzbekistan 24
BE - Belgio 23
MY - Malesia 23
AU - Australia 19
CL - Cile 18
CR - Costa Rica 17
PH - Filippine 17
PE - Perù 16
TW - Taiwan 16
EG - Egitto 14
AE - Emirati Arabi Uniti 13
IL - Israele 13
PT - Portogallo 13
JM - Giamaica 12
PY - Paraguay 12
TH - Thailandia 12
JO - Giordania 11
LT - Lituania 11
MA - Marocco 11
SA - Arabia Saudita 11
GR - Grecia 10
RO - Romania 10
A2 - ???statistics.table.value.countryCode.A2??? 9
IR - Iran 9
UY - Uruguay 9
NP - Nepal 7
PA - Panama 7
DZ - Algeria 6
HU - Ungheria 6
KZ - Kazakistan 6
TN - Tunisia 6
TT - Trinidad e Tobago 6
AL - Albania 5
ET - Etiopia 5
KE - Kenya 5
KH - Cambogia 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
SV - El Salvador 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CH - Svizzera 4
EU - Europa 4
HN - Honduras 4
MK - Macedonia 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
OM - Oman 3
SY - Repubblica araba siriana 3
BH - Bahrain 2
BO - Bolivia 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
NG - Nigeria 2
NO - Norvegia 2
PR - Porto Rico 2
SN - Senegal 2
AM - Armenia 1
BS - Bahamas 1
Totale 62.911
Salva come PNG Salva come JPEG
Città #
Wilmington 11.608
Houston 11.260
Woodbridge 10.252
Fairfield 1.944
Singapore 1.713
Ashburn 1.294
Ann Arbor 989
San Jose 918
Seattle 809
Hong Kong 796
Chandler 749
Cambridge 669
Dublin 567
Council Bluffs 504
Beijing 436
Medford 422
Jacksonville 354
Dearborn 325
Santa Clara 324
New York 288
Kraków 280
Los Angeles 270
Rome 254
The Dalles 246
Ho Chi Minh City 211
Lawrence 195
Lauterbourg 172
Tokyo 168
Dallas 163
Hanoi 156
Moscow 139
Boardman 138
Colorado Springs 129
Buffalo 122
Zhengzhou 121
San Diego 119
Chicago 118
Helsinki 109
São Paulo 99
Monte Vista 95
Milan 94
Menlo Park 74
Naples 73
London 55
Phoenix 47
Orem 45
Norwalk 44
Redondo Beach 43
Brooklyn 41
North Bergen 41
Jakarta 40
Denver 39
Nuremberg 39
Redwood City 39
Shanghai 39
Toronto 39
Bar Harbor 38
Atlanta 35
Guangzhou 35
San Francisco 34
Warsaw 32
Montreal 30
Salt Lake City 30
Columbus 29
Frankfurt am Main 29
Rio de Janeiro 28
Nanjing 27
Chennai 26
Hangzhou 26
Hefei 24
Mountain View 24
Verona 23
Lappeenranta 22
Palo Alto 22
Stockholm 22
Belo Horizonte 21
Brussels 20
Haiphong 20
Tashkent 20
Detroit 19
Elk Grove Village 18
Munich 18
Tampa 18
Da Nang 17
Kunming 17
Miami 17
Mülheim 17
Poplar 17
Boston 16
Brasília 16
Chengdu 16
Jinan 16
Parma 16
Saint Petersburg 16
San José 16
Turin 16
Charlotte 15
Johannesburg 15
Philadelphia 15
Seoul 15
Totale 51.280
Salva come PNG Salva come JPEG
Nome #
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 517
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 511
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 509
Interaction between corticosteroids and muscarinic antagonists in human airways 506
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 504
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 503
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 492
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 491
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 491
A Novel and Effective Balanced Intravenous-Inhalant Anaesthetic Protocol in Swine by Using Unrestricted Drugs 487
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 487
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 487
Asthma and comorbid medical illness. 484
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 484
Optimizing drug delivery in COPD: The role of inhaler devices 483
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 479
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 475
Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells 472
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 472
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 470
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 466
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 466
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 461
Occupational allergy to horse allergens: More than exposure to horses! 460
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis 455
Umeclidinium for the treatment of chronic obstructive pulmonary disease 452
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 450
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? 449
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? 448
The prevalence of asthma and COPD in Italy: a practice-based study 447
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 447
Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? 447
Tiotropium formulations and safety: a network meta-analysis 447
Asthma and comorbid medical illness 441
Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review 440
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis 438
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 435
Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling 435
How many systemic reactions to skin prick tests could be preventable in defined conditions? 435
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 435
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 435
Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD 434
New Treatments for COPD in the Elderly 433
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 433
Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in “real life”? 433
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 432
The Challenges of Precision Medicine in COPD 432
Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis 431
Brensocatib: Dipeptidyl peptidase 1 (DPP1) inhibitor Treatment of non-cystic fibrosis bronchiectasis 431
The effect of indacaterol during an acute exacerbation of COPD 428
Dog allergen immunotherapy and allergy to furry animals 428
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 428
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 425
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 425
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 423
The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. 423
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 423
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 421
Translational study searching for synergy between glycopyrronium and indacaterol 421
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 421
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 420
Comorbidities of asthma 418
Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies 418
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 416
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 415
Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity 413
Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience 412
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 411
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 403
Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? 400
What could the role of can f 5 allergen be in dog-sensitized patients in “real life”? 397
Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy? 397
Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways 394
Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens 393
The clinical use of regenerative therapy in COPD 393
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 391
Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection? 390
Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? 390
Partial nephrectomy using radiofrequency incremental bipolar generator with multi electrode probe: experimental study in bench pig kidneys 389
Partial renal resection by LaparoNewPro: in vivo open and laparoscopic study in an animal model 385
Diabetes mellitus among outpatients with COPD attending a university hospital. 378
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 378
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: An Italian Multicenter Study 377
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 376
Relationship between oxytocin/vasopressin and latex in obstetric surgery: How to recognize (and prevent) allergic reactions and differentiate them from side effects? 376
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine 375
Anaphylaxis and intimate behaviour 371
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 363
Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue 363
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 363
Brain natriuretic peptide: Much more than a biomarker 362
Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link? 362
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 362
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 360
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi 356
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma 353
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how 348
Canakinumab for the treatment of chronic obstructive pulmonary disease 344
Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi 329
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 327
Totale 42.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 173.437
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.437
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.766 0 173 30 31 54 186 218 76 115 203 182 498
2022/20232.109 264 148 60 236 167 537 205 126 199 14 91 62
2023/2024928 196 23 59 16 62 145 68 118 37 52 19 133
2024/20255.702 163 1.180 601 286 187 228 485 263 488 626 624 571
2025/20269.368 588 480 1.011 695 1.074 429 1.212 1.108 1.182 650 547 392
2026/20271.644 1.066 578 0 0 0 0 0 0 0 0 0 0
Totale 63.756